Management Team

Mr. Iwicki has more than 30 years of biopharmaceutical industry experience. He was previously Chief Executive Officer of KALA BIO. Mr. Iwicki currently serves as the Chair of board of directors of KALA BIO and also serves on the boards of directors of Nimbus, Akero Therapeutics, Third Harmonic Bio, Q32 Bio and Merus. He previously served as President and Chief Executive Officer of Civitas Therapeutics and Sunovion Pharmaceuticals Inc. He was also President and Chief Executive Officer of Blend Therapeutics, and President and Chief Operating Officer at Sepracor. Earlier in his career, he was Vice President and Business Unit Head at Novartis Pharmaceuticals Corporation and held management positions at Astra Merck Inc. and Merck & Co. He previously served on the board of Aimmune Therapeutics. Mr. Iwicki holds a B.S. in Business Administration from Ball State University and an M.B.A. from Loyola University.

Dr. Chris Cabell is the President, Head of Research and Development, and Chief Medical Officer of Inhibikase Therapeutics. Prior to this, Dr. Cabell served as Chief Executive Officer of CorHepta Pharmaceuticals which was acquired by Inhibikase. Previously, he served as Head of Clinical Development and CMO at Zura Bio and Emergent BioSolutions. Prior to that he spent 3 years at Arena Pharmaceuticals with increasing responsibilities including Chief Medical Officer and Head of Research and Development and he started his career as an Associate Professor of Medicine in the Division of Cardiology, Department of Medicine, Duke University School of Medicine. Dr. Cabell is a Fellow of the American College of Cardiology and has over 100 peer reviewed publications including in the New England Journal of Medicine, JAMA, and Annals of Internal Medicine. Board certified in both internal medicine and cardiovascular diseases, Dr. Cabell is a honors graduate of Pennsylvania State University and Duke University, earning both his Medical Degree and a Masters in Health Sciences from the latter.

Dr. Adams joins Inhibikase from CorHepta where he was co-founder and Chief Scientific Officer. Previously he was Senior Vice President of Discovery Biology at Iambic Therapeutics, Senior Vice President of Translational Science at Reneo Pharmaceuticals, and the Head of Research at Arena Pharmaceuticals. Dr. Adams earned his PhD in Physiological Science at UCLA and his B.S. Biological Sciences from U.C. Santa Barbara.

Garth Lees-Rolfe, has served as our Chief Financial Officer since April 2024 and previously as our Vice President of Finance since November 2022. Mr. Lees-Rolfe previously served as the Vice-President, Finance for F-Star, Inc., a publicly traded global clinical-stage biotech company. Prior to that, Mr. Lees-Rolfe worked for 16 years in public practice, most of which was with Ernst & Young, most recently as Senior Manager. Mr. Lees-Rolfe earned a Bachelor of Business from the Queensland University of Technology and a Graduate Certificate in Applied Finance from Kaplan Professional. He is a licensed Certified Public Accountant in the state of Massachusetts and a licensed Chartered Accountant of Australia and New Zealand.

Jeff brings a wealth of experience leading human resources & corporate administration in fast-growing life sciences organizations. He has a solid mix of private and public company experience, as well as, a deep talent acquisition, talent management, & organizational development background. Prior to 2008, Jeff successfully managed his own HR consulting practice for over 15 years.

Chad Orevillo has over 30 years of experience in pharmaceutical clinical development and operations and program management. Prior to joining Inhibikase, he was co-founder and Executive Vice President and Head of Operations for Longboard Pharmaceuticals and before that served as Vice President and Head of Clinical Operations at Arena Pharmaceuticals. Earlier in his career, Chad held management roles at Merck, Pharmacia, Pfizer, Novartis, Pearl Therapeutics and Astrazeneca. Chad holds a Master in Public Health from Tulane University, a Bachelor of Science from William Paterson University and is a US Marine Corps veteran.